Remdesivir was one of the first medications approved for treatment of COVID-19. Clinical studies evaluated its effectiveness, but did not generate conclusive results. A new analysis of the study data shows that a specific ...
Feb 22, 2023
1
24
Do patients with prolonged infections contribute to the emergence of new SARS-CoV-2 variants? A research team from the Leibniz Institute of Virology (LIV) and the University Medical Center Hamburg-Eppendorf (UKE) has investigated ...
Aug 17, 2022
0
75
A monoclonal antibody treatment taken by patients hospitalized with COVID-19 did not improve recovery time but did reduce deaths, according to a study published July 8 in The Lancet Respiratory Medicine.
Jul 11, 2022
0
139
Determining how SARS-CoV-2, the virus causing COVID-19, moves from an early stage of infection, when patients are largely asymptomatic, into a later stage in which people may experience life-threatening inflammation in the ...
Jun 14, 2022
0
186
The virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.
May 4, 2022
0
107
Scientists at the University of North Carolina at Chapel Hill are testing a new route for remdesivir, a pill form of the COVID-19 treatment that's given to half of all hospitalized patients with the disease.
Mar 22, 2022
0
79
Researchers have identified a powerful combination of antivirals to treat COVID-19. Combining the drug brequniar with remdesivir or molnupiravir—both approved by the U.S. Food and Drug Administration for emergency use—inhibited ...
Feb 7, 2022
0
454
Remdesivir is currently the only antiviral drug approved in the U.S. for treating COVID-19 patients. In a paper published this week in Cell Reports, researchers from The University of Texas at Austin, Rensselaer Polytechnic ...
Apr 27, 2021
0
196
In the treatment of SARS-CoV-2, the virus that causes COVID-19, antiviral drug remdesivir has emerged as a promising candidate.
Jan 29, 2021
0
201
A large team of researchers affiliated with a host of institutions in the U.S., France and Spain has found that the drug plitidepsin worked better at treating COVID-19 than did remdesivir in a lab setting. In their paper ...
